Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Indaptus Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Indaptus Therapeutics, Inc.’s stock price such as:

• Indaptus Therapeutics, Inc.’s current stock price and volume
• Why Indaptus Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for INDP from analysts
• INDP’s stock price momentum as measured by its relative strength

About Indaptus Therapeutics, Inc. (INDP)

Before we jump into Indaptus Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Want to learn more about Indaptus Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Indaptus Therapeutics, Inc..

Indaptus Therapeutics, Inc.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, Indaptus Therapeutics, Inc.’s stock price was $1.290.

Indaptus Therapeutics, Inc. is down 6.52% from its previous closing price of $1.380.

During the last market session, Indaptus Therapeutics, Inc.’s stock traded between $1.180 and $1.580. Currently, there are approximately 116.13 million shares outstanding for Indaptus Therapeutics, Inc..

Indaptus Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Indaptus Therapeutics, Inc. Stock Price History

During the month of August, Indaptus Therapeutics, Inc.’s stock price has not significantly increased or decreased. In order to understand the stock price forecast for Indaptus Therapeutics, Inc., you may need to analyze their annual trend or other metrics instead.

Over the last year, Indaptus Therapeutics, Inc. has hit prices as high as $8.570 and as low as $0.920. Year to date, Indaptus Therapeutics, Inc.’s stock is down 55.67%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Indaptus Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 20, 2026, there were analysts who downgraded Indaptus Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Indaptus Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Indaptus Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Indaptus Therapeutics, Inc. (INDP) by visiting AAII Stock Evaluator.

Relative Price Strength of Indaptus Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 20, 2026, Indaptus Therapeutics, Inc. has a weighted four-quarter relative price strength of -17.30%, which translates to a Momentum Score of 13 and is considered to be Very Weak.

Want to learn more about how Indaptus Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Indaptus Therapeutics, Inc. Stock Price: Bottom Line

As of August 21, 2026, Indaptus Therapeutics, Inc.’s stock price is $1.290, which is down 6.52% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Indaptus Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.